Skip to main content
. 2022 Jan 18;5(6):zrab137. doi: 10.1093/bjsopen/zrab137

Table 4.

EORTC QLQ-C30 three-arm randomization

EORTC QLQ-C30 SRT (n = 51)
SRT-delay (n = 57)
LRT-delay (n = 61)
P
Mean scale score (s.d.) Mean scale score (s.d.) Mean scale score (s.d.)
Global health status 75 (19) 71(23) 71(21) 0.494
Functional scales
 Physical functioning 86 (19) 85 (19) 84 (18) 0.851
 Role functioning 81 (28) 82 (27) 79 (27) 0.868
 Emotional functioning 86 (19) 82 (19) 84 (19) 0.525
 Cognitive functioning 88 (16) 85 (17) 91 (17) 0.698
 Social functioning 74 (28) 76 (29) 76 (29) 0.905
Symptoms
 Fatigue 21 (21) 24 (23) 24 (24) 0.626
 Nausea and vomiting 6 (12) 6 (16) 2 (7) 0.091
 Pain 19 (26) 19 (26) 17 (26) 0.812
Single items
 Dyspnoea 16 (22) 19 (24) 19 (25) 0.714
 Insomnia 20 (25) 21 (29) 21 (29) 0.963
 Appetite loss 5 (12) 6 (18) 10 (24) 0.397
 Constipation 17 (27) 14 (24) 15 (29) 0.791
 Diarrhoea 23 (30) 22 (31) 19 (30) 0.752
 Financial difficulties 2 (11) 10 (23) 9 (20) 0.074

EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30, Quality of Life Core Questionnaire C30, version 3.0; SRT, short-course radiotherapy and surgery within 1 week; SRT-delay, short-course radiotherapy, with surgery after 4–8 weeks; LRT-delay, long-course radiotherapy of 25 × 2 Gy, with surgery after 4–8 weeks.